{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:20:35Z","timestamp":1787815235839,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["TRR 387\/1\\u2013514894665"],"award-info":[{"award-number":["TRR 387\/1\\u2013514894665"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.mcpro.2026.101615","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:47:10Z","timestamp":1782492430000},"page":"101615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteome Profiling Reveals NQO2 Activity Contributing to Proteasome Inhibitor Resistance in Multiple Myeloma Cell Lines"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-6374","authenticated-orcid":false,"given":"Chien-Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-3102","authenticated-orcid":false,"given":"Seungbin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Haertle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-9923","authenticated-orcid":false,"given":"Umair","family":"Munawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5872-1909","authenticated-orcid":false,"given":"Johanna","family":"Streubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-1677","authenticated-orcid":false,"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2026.101615_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.mcpro.2026.101615_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mcpro.2026.101615_bib3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcpro.2026.101615_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcpro.2026.101615_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematol. Am Soc Hematol Educ Program"},{"key":"10.1016\/j.mcpro.2026.101615_bib6","article-title":"Carfilzomib in relapsed\/refractory multiple myeloma patients - real world evidence - experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","volume":"43","author":"Galusic","year":"2025","journal-title":"Cancer Treat Res. Commun."},{"key":"10.1016\/j.mcpro.2026.101615_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.mcpro.2026.101615_bib8","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2026.101615_bib9","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.mcpro.2026.101615_bib10","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2026.101615_bib11","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2026.101615_bib12","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2026.101615_bib13","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1007\/s00018-021-03756-3","article-title":"Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma","volume":"78","author":"Xiong","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.mcpro.2026.101615_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.mcpro.2026.101615_bib15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.chembiol.2009.11.015","article-title":"Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites","volume":"16","author":"Britton","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.mcpro.2026.101615_bib16","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2026.101615_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2026.101615_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2026.101615_bib19","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2026.101615_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2026.101615_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2026.101615_bib22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/bloodadvances.2018016360","article-title":"An inhibitor of proteasome beta2 sites sensitizes myeloma cells to immunoproteasome inhibitors","volume":"2","author":"Downey-Kopyscinski","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.mcpro.2026.101615_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: Head-to-Head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.mcpro.2026.101615_bib24","first-page":"634","article-title":"Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?","volume":"4","author":"Bo Kim","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.mcpro.2026.101615_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1007","article-title":"Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance","volume":"7","author":"Nikesitch","year":"2018","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.mcpro.2026.101615_bib26","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2026.101615_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.mcpro.2026.101615_bib28","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2026.101615_bib29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2026.101615_bib30","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2026.101615_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2026.101615_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.mcpro.2026.101615_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101189","article-title":"Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states","volume":"66","author":"Kamal","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.mcpro.2026.101615_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12014-025-09560-6","article-title":"Novel proteomic characterization of multiple myeloma bone marrow interstitial fluid links prognosis to coagulation pathways","volume":"22","author":"Cutler","year":"2025","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.mcpro.2026.101615_bib35","doi-asserted-by":"crossref","first-page":"56726","DOI":"10.18632\/oncotarget.11059","article-title":"Comparative proteomic profiling of refractory\/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy","volume":"7","author":"Dytfeld","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcpro.2026.101615_bib36","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.jproteome.9b00217","article-title":"Universal solid-phase protein preparation (USP(3)) for Bottom-up and top-down proteomics","volume":"18","author":"Dagley","year":"2019","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.mcpro.2026.101615_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","article-title":"Single-pot, solid-phase-enhanced sample preparation for proteomics experiments","volume":"14","author":"Hughes","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mcpro.2026.101615_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1074\/mcp.RA120.002164","article-title":"Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing","volume":"19","author":"Zecha","year":"2020","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2026.101615_bib39","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1074\/mcp.TIR119.001385","article-title":"TMT labeling for the masses: a robust and cost-efficient, In-solution labeling approach","volume":"18","author":"Zecha","year":"2019","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2026.101615_bib40","first-page":"28","article-title":"Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics","volume":"20","author":"Lee","year":"2024","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2026.101615_bib41","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1021\/acs.analchem.1c00257","article-title":"Robust microflow LC-MS\/MS for proteome analysis: 38 000 runs and counting","volume":"93","author":"Bian","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.mcpro.2026.101615_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100238","article-title":"SIMSI-Transfer: Software-Assisted reduction of missing values in phosphoproteomic and proteomic isobaric labeling data using Tandem mass spectrum clustering","volume":"21","author":"Hamood","year":"2022","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2026.101615_bib43","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1038\/s41467-020-17336-9","article-title":"Proteome activity landscapes of tumor cell lines determine drug responses","volume":"11","author":"Frejno","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2026.101615_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-4939-3049-4_21","article-title":"From phosphosites to kinases","volume":"1355","author":"Munk","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"Suppl 16","key":"10.1016\/j.mcpro.2026.101615_bib45","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/1471-2105-13-S16-S12","article-title":"1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data","volume":"13","author":"Cox","year":"2012","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.mcpro.2026.101615_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-026-02115-y","article-title":"Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma","volume":"18","author":"Han","year":"2026","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.mcpro.2026.101615_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105091","article-title":"Investigation of cancer drug resistance mechanisms by phosphoproteomics","volume":"160","author":"Boulos","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mcpro.2026.101615_bib48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s44320-025-00141-1","article-title":"Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures","volume":"21","author":"Hsu","year":"2025","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2026.101615_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091784","article-title":"Kinase inhibition in multiple myeloma: current scenario and clinical perspectives","volume":"14","author":"Barreto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mcpro.2026.101615_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010238","article-title":"Cytoskeletal proteins in cancer and intracellular stress: a therapeutic perspective","volume":"12","author":"Ong","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2026.101615_bib51","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77780","article-title":"The integrated stress response remodels the microtubule-organizing center to clear unfolded proteins following proteotoxic stress","volume":"11","author":"Hurwitz","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.mcpro.2026.101615_bib52","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1073\/pnas.052706799","article-title":"NQO1 stabilizes p53 through a distinct pathway","volume":"99","author":"Asher","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2026.101615_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molcel.2012.05.049","article-title":"A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1","volume":"47","author":"Moscovitz","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.mcpro.2026.101615_bib54","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2026.101615_bib55","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947626001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947626001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:06:46Z","timestamp":1787814406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947626001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1535947626001118"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2026.101615","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteome Profiling Reveals NQO2 Activity Contributing to Proteasome Inhibitor Resistance in Multiple Myeloma Cell Lines","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2026.101615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101615"}}